MAP Pharmaceuticals (MAPP) Receives FDA CRL for LEVADEX
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Join SI Premium – FREE
Late Monday, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced the FDA issued a Complete Response letter (CRL) to its New Drug Application (NDA) for LEVADEX inhalation aerosol.
In the CRL, the FDA requested that the Company address issues relating to chemistry, manufacturing and controls (CMC) and observations from a recent facility inspection of a third party manufacturer. The FDA also indicated that it had not been able to complete review of inhaler usability information requested late in the review cycle by the FDA.
The FDA did not cite any clinical safety or efficacy issues, nor did the FDA request that any additional clinical studies be conducted prior to approval.
MAP Pharmaceuticals will Host Conference Call on Tuesday, March 27, 8:00 a.m. Eastern Time.
Shares remain halted on the NASDAQ at this time.
In the CRL, the FDA requested that the Company address issues relating to chemistry, manufacturing and controls (CMC) and observations from a recent facility inspection of a third party manufacturer. The FDA also indicated that it had not been able to complete review of inhaler usability information requested late in the review cycle by the FDA.
The FDA did not cite any clinical safety or efficacy issues, nor did the FDA request that any additional clinical studies be conducted prior to approval.
MAP Pharmaceuticals will Host Conference Call on Tuesday, March 27, 8:00 a.m. Eastern Time.
Shares remain halted on the NASDAQ at this time.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
- Trump admin taps former JPMorgan Chase exec Matt Zames to advise social security agency - CNBC
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
